Background: Progression diets after bariatric surgery (BS) are restricted in calories and protein, and they may induce a worsening of body composition. The aim of this study was to evaluate the effect of a modified diet with an oral nutritional supplement that is hyperproteic and normocaloric over the body composition. Methods: A two-arm ambispective observational cohort study was designed. Forty-four patients who underwent sleeve gastrectomy were included in the study. Thirty patients received a progression diet with a normocaloric, hyperproteic oral nutritional supplement during the first two weeks after surgery (820 kcal, 65.5 g protein). They were compared with a historical cohort of 14 patients treated with a standard progression diet (220 kcal, 11.5 g protein). Anthropometric and body composition (using electrical bioimpedanciometry) data were analyzed before BS and 1 month after the surgery. Results: The mean age was 47.35(10.22) years; 75% were women, and the average presurgical body mass index (BMI) was 45.98(6.13) kg/m2, with no differences between both arms of intervention. One month after surgery, no differences in the percentage of excess weight loss (%PEWL) were observed between patients in the high-protein-diet group (HP) and low-protein-diet group (LP) (HP: 21.86 (12.60)%; LP: 18.10 (13.49)%; p = 0.38). A lower loss of appendicular skeletal muscle mass index was observed in the HP (HP: −5.70 (8.79)%; LP: −10.54 (6.29)%; p < 0.05) and fat-free mass index (HP: 3.86 (8.50)%; LP:−9.44 (5.75)%; p = 0.03), while a higher loss of fat mass was observed in the HP (HP: −14.22 (10.09)%; LP: −5.26 (11.08)%; p < 0.01). Conclusions: In patients undergoing gastric sleeve surgery, the addition of a normocaloric, hyperproteic formula managed to slow down the loss of muscle mass and increase the loss of fat mass with no differences on total weight loss.
Epithelial ovarian cancer is one of the most common causes of cancer-related death in women. More than half of patients are diagnosed at an advanced stage, usually due to the locoregional spread of peritoneal carcinomatosis. We present the case of a 49-year-old woman who suffered from constitutional syndrome and abdominal distention. The imaging tests revealed two large, vascularized, and heterogeneous masses that depended on both ovaries. Bilateral adnexectomy was performed and the result of the anatomopathological study was endometrioid carcinoma moderately differentiated. The patient was treated according to the latest recommendations of the NCCN guidelines. A combination of systemic chemotherapy and cytoreductive surgery has been the standard treatment since the mid-1990s. However, a combination of hyperthermic intravenous and intraperitoneal chemotherapy may reduce plasma toxicity and increase therapeutic effectiveness.
Background and aim . Combined hepatocellular-cholangiocarcinoma (cHCC-CCA) is a rare liver malignancy, which comprises clinical and morphological features of both hepatocellular carcinoma (HCC) and cholangiocarcinoma (CC) and corresponds to 1–4.7% of cases of primary liver carcinomas. At present, Liver transplantation (LT) is not routinely recommended for known cHCC-CCA due to concerns regarding aggressive behavior and recurrence risk. However, incidental diagnoses after LT performed for presumed HCC raise questions regarding post-transplant outcomes. Material and methods . We conducted a retrospective single-center study including patients who underwent LT between 2000 and 2025. Patients with incidentally diagnosed cHCC-CCA on explant pathology were matched 1 : 2 with HCC controls according to age, year of transplantation, donor type, tumor burden at explant (number and size), lymphovascular invasion, locoregional therapy, and BAR score. Overall survival (OS) and disease-free survival (DFS) were analyzed using Kaplan–Meier estimates and compared with the log-rank test. Results . After matching, 9 patients with cHCC-CCA were matched with 18 HCC controls. Five-year OS was 41.7% in the cHCC-CCA group and 81.5% in the HCC group (p = 0.26) and Five-year DFS was 70% versus 85.9%, respectively (p = 0.25). Recurrence occurred in two patients in each group. To date, this 25-year study represents one of the most rigorously matched European analyses, uniquely incorporating lymphovascular invasion and BAR score as matching variables. Conclusions . Despite the fact that no statistically significant differences were demonstrated in post-transplant survival or recurrence between the groups, worse results could be observed in the studied group, which is consistent with the current non-indication of LT for cHCC-CCA. This study was substantially underpowered, so the absence of statistical significance should not be interpreted as clinical equivalence.
21 September 2026 in Journal of Clinical and Experimental Hepatology